Last reviewed · How we verify
Sequential BCG and EMDA mitomycin C
Sequential BCG immunotherapy followed by EMDA-enhanced mitomycin C chemotherapy provides combined immunological and chemotherapeutic effects for intravesical bladder cancer treatment.
Sequential BCG immunotherapy followed by EMDA-enhanced mitomycin C chemotherapy provides combined immunological and chemotherapeutic effects for intravesical bladder cancer treatment. Used for Non-muscle invasive bladder cancer (NMIBC), high-risk disease.
At a glance
| Generic name | Sequential BCG and EMDA mitomycin C |
|---|---|
| Also known as | Sequential BCG and EMDA-MMC |
| Sponsor | Turku University Hospital |
| Drug class | Combination immunotherapy and chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BCG (Bacillus Calmette-Guérin) stimulates local immune responses in the bladder to eliminate cancer cells. EMDA (electromotive drug administration) uses electrical current to enhance penetration of mitomycin C into bladder tissue, improving chemotherapeutic efficacy. The sequential combination leverages both immune activation and enhanced drug delivery.
Approved indications
- Non-muscle invasive bladder cancer (NMIBC), high-risk disease
Common side effects
- Dysuria
- Urinary frequency
- Hematuria
- Local irritation
- Systemic BCG toxicity
Key clinical trials
- Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer (PHASE3)
- Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection (NA)
- Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequential BCG and EMDA mitomycin C CI brief — competitive landscape report
- Sequential BCG and EMDA mitomycin C updates RSS · CI watch RSS
- Turku University Hospital portfolio CI